View original document

The full text on this page is automatically extracted from the file linked above and may contain errors and inconsistencies.

Federal Register / Vol. 77, No. 45 / Wednesday, March 7, 2012 / Proposed Rules
Options range from recalls to export
information to regulations, directives,
and notices. Customers can add or
delete subscriptions themselves, and
have the option to password protect
their accounts.
USDA Nondiscrimination Statement
USDA prohibits discrimination in all
its programs and activities on the basis
of race, color, national origin, gender,
religion, age, disability, political beliefs,
sexual orientation, and marital or family
status (Not all prohibited bases apply to
all programs).
Persons with disabilities who require
alternative means for communication of
program information (Braille, large
print, and audiotape) should contact
USDA’s Target Center at (202) 720–2600
(voice and TTY).
To file a written complaint of
discrimination, write USDA, Office of
the Assistant Secretary for Civil Rights,
1400 Independence Avenue SW.,
Washington, DC 20250–9410 or call
(202) 720–5964 (voice and TTY). USDA
is an equal opportunity provider and
Done at Washington, DC, on March 5,
Alfred V. Almanza,
[FR Doc. 2012–5656 Filed 3–5–12; 4:15 pm]

12 CFR Part 252
[Regulation YY; Docket No. 1438]
RIN 7100–AD–86

Enhanced Prudential Standards and
Early Remediation Requirements for
Covered Companies
Board of Governors of the
Federal Reserve System (Board).
ACTION: Proposed rule; extension of
comment period.

On January 5, 2012, the Board
published in the Federal Register a
notice of proposed rulemaking for
public comment to implement the
enhanced prudential standards required
to be established under section 165 of
the Dodd-Frank Wall Street Reform and
Consumer Protection Act (Dodd-Frank
Act or Act) and the early remediation
requirements established under section
166 of the Act.
Due to the range and complexity of
the issues addressed in the rulemaking,
the Board has determined that an



VerDate Mar<15>2010

16:53 Mar 06, 2012

Jkt 226001

extension of the end of the public
comment period from March 31, 2012,
until April 30, 2012, is appropriate. This
action will allow interested persons
additional time to analyze the proposed
rules and prepare their comments.
DATES: Comments on the proposed rule
must be received on or before April 30,
ADDRESSES: You may submit comments
by any of the methods identified in the
proposed rule.1 Please submit your
comments using only one method.
Molly E. Mahar, Senior Supervisory
Financial Analyst, (202) 973–7360,
Division of Banking Supervision and
Regulation; or Laurie Schaffer, Associate
General Counsel, (202) 452–2272, or
Dominic A. Labitzky, Senior Attorney,
(202) 452–3428, Legal Division.
proposed rule was published in the
Federal Register on January 5, 2012,2
and would implement the enhanced
prudential standards required to be
established under section 165 of the
Dodd-Frank Act and the early
remediation requirements established
under section 166 of the Act. The
enhanced standards include risk-based
capital and leverage requirements,
liquidity standards, requirements for
overall risk management (including
establishing a risk committee), singlecounterparty credit limits, stress test
requirements, and a debt-to-equity limit
for companies that the Financial
Stability Oversight Council has
determined pose a grave threat to
financial stability.
In recognition of the complexities of
the issues addressed and the variety of
considerations involved with
implementation of the proposal, the
Board requested that commenters
respond to numerous questions. The
proposed rule stated that the public
comment period would close on March
31, 2012.3
The Board has received requests from
the public for an extension of the
comment period to allow for additional
time for comments related to the
provisions of the proposed rule.4 The
Board believes that the additional
period for comment will facilitate
public comment on the provisions of the
proposed rule and the questions posed
by the Board. Therefore, the Board is
1 See Enhanced Prudential Standards and Early
Remediation Requirements for Covered Companies,
77 FR 594 (Jan. 5, 2012).
2 Id.
3 Id.
4 See, e.g., Comment letters to the Board from The
Clearing House et al. (Jan. 25, 2012); and The
Geneva Association (Feb. 13, 2013).

PO 00000

Frm 00002

Fmt 4702

Sfmt 4702


extending the comment period for the
proposed rule from March 31, 2012 to
April 30, 2012.
By order of the Board of Governors of the
Federal Reserve System, acting through the
Secretary under delegated authority, March
2, 2012.
Jennifer J. Johnson,
Secretary of the Board.
[FR Doc. 2012–5522 Filed 3–6–12; 8:45 am]

Food and Drug Administration
21 CFR Chapter I
[Docket No. FDA–2012–N–0170]

Modernizing the Regulation of Clinical
Trials and Approaches to Good
Clinical Practice; Public Hearing;
Request for Comments

Food and Drug Administration,

Notification of public hearing;
request for comments.


The Food and Drug
Administration (FDA) is announcing a
2-day public hearing to obtain input
from interested persons on FDA’s scope
and direction in modernizing the
regulations, policies, and practices that
apply to the conduct of clinical trials of
FDA-regulated products. Clinical trials
are a critical source of evidence to
inform medical policy and practice, and
effective regulatory oversight is needed
to ensure that human subjects are
protected and resulting clinical trial
data are credible and accurate. FDA is
aware of concerns within the clinical
trial community that certain regulations
and policies applicable to the conduct
of clinical trials may result in
inefficiencies or increased cost and may
not facilitate the use of innovative
methods and technological advances to
improve clinical trial quality. The
Agency is involved in an effort to
modernize the regulatory framework
that governs clinical trials and
approaches to good clinical practice
(GCP). The purpose of this hearing is to
solicit public input from a broad group
of stakeholders on the scope and
direction of this effort, including
encouraging the use of innovative
models that may enhance the
effectiveness and efficiency of the
clinical trial enterprise.
DATES: Date and Time: The public
hearing will be held on April 23 and 24,
2012, from 8:30 a.m. to 4:30 p.m.